Storia: So Far, So Good for PCSK9-Targeting Gene Therapy in Hypercholesterolemia

WARPTECHNEWS · LAB

Eli Lilly said a base editing gene therapy from its purchase of Verve Therapeutics delivered additional positive results in a Phase 1b trial, paving the way for a mid-stage test…

So Far, So Good for PCSK9-Targeting Gene Therapy in Hypercholesterolemia

Confronto fonti

So Far, So Good for PCSK9-Targeting Gene Therapy in Hypercholesterolemia

Timeline cronologica

A single dose of Lilly's PCSK9 base editor, VERVE-102, reduced PCSK9 by up to 88% and LDL-C by up to 62%, with durable effects supporting…

Lilly reports new data on PCSK9 base editing gene therapy from Verve buyout

PCSK9 inhibition via base editing lowers LDL in patients with genetic high cholesterol

A single dose of Lilly's PCSK9 base editor, VERVE-102, reduced PCSK9 by up to 88% and LDL-C by up to 62%,…

Bad cholesterol slashed 62% by single dose of gene-editing drug in small trial

Lilly reports new data on PCSK9 base editing gene therapy from Verve buyout

Gene-editing drugs are opening a new frontier in medicine

Gene-editing drugs are opening a new frontier in medicine

So Far, So Good for PCSK9-Targeting Gene Therapy in Hypercholesterolemia

Bad cholesterol slashed 62% by single dose of gene-editing drug in small trial

One dose of gene-editing drug cut bad cholesterol 62% for months in small trial

PCSK9 inhibition via base editing lowers LDL in patients with genetic high cholesterol